Medistim

R&D Investments May Impact Margins, But New Products Could Boost Future Revenue

AnalystConsensusTarget

Not Invested

Consensus Narrative from 2 Analysts

Published

06 Feb 25

Updated

14 Aug 25

AnalystConsensusTarget's Fair Value

NOK 230.00

2.2% undervalued

14 Aug

NOK 225.00

40.6%

Author's Valuation

NOK 230.0

2.2% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates1

Shared on13 Mar 25
Fair value Increased 2.22%

AnalystConsensusTarget Fair Value

NOK 230.0

2.2% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

7.68%

Medical Equipment revenue growth rate

0.44%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.81%

Calculation

NOK 160.00m

Earnings '28

31.53x

PE Ratio '28

NOK 5.04b

Market Cap '28

NOK 5.04b

Market Cap '28

18.14m

No. shares '28

NOK 278.00

Share Price '28

NOK 278.00 Share Price '28

Discounted to 2025 @ 6.81% p.a.

NOK 228.17

Fair Value '25

R&D Investments May Impact Margins, But New Products Could Boost Future Revenue

Shared on13 Mar 25Fair value Increased 2.22%

Shared on13 Mar 25
Fair value Increased 2.22%